Among the measures ImmunityBio has implemented are “expanded promotional review protocols,” executive training and external ...

The doctors at fictional Sacred Heart Hospital are in, and so is Insulet’s real-life wearable insulin management system ...

A phase 3 trial of patients with moderate-to-severe TED has shown that subcutaneous injection of Tepezza by way of an on-body ...

Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. | ...

VML Health, a marketing and communications company, has identified the concept's emergence as a trend affecting how ...

After shedding expensive commercial infrastructure and pivoting to a partnership model, the company is now positioning its ...

Forget March going out like a lamb. On the M&A landscape, March went out like a lion.  | In a flurry of activity, biopharma ...

Amgen’s rare disease drug Tavneos is under mounting regulatory scrutiny, with the FDA warning of serious liver injuries, ...

For more than a year, the biopharma industry has had to swiftly react to various tariff threats from the Trump administration. | The president has rolled out a 100% tariff rate on patented ...

Iterum took its time launching Orlynvah, debuting the drug in August 2025, almost a full year after securing approval. That ...

With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...

With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...